Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Commun Biol ; 4(1): 386, 2021 03 22.
Article in English | MEDLINE | ID: mdl-33753867

ABSTRACT

APOBEC3A (A3A) and APOBEC3B (A3B) enzymes drive APOBEC-mediated mutagenesis. Identification of factors affecting the activity of these enzymes could help modulate mutagenesis and associated clinical outcomes. Here, we show that canonical and alternatively spliced A3A and A3B isoforms produce corresponding mutagenic and non-mutagenic enzymes. Increased expression of the mutagenic A3B isoform predicted shorter progression-free survival in bladder cancer. We demonstrate that the production of mutagenic vs. non-mutagenic A3B protein isoforms was considerably affected by inclusion/skipping of exon 5 in A3B. Furthermore, exon 5 skipping, resulting in lower levels of mutagenic A3B enzyme, could be increased in vitro. Specifically, we showed the effects of treatment with an SF3B1 inhibitor affecting spliceosome interaction with a branch point site in intron 4, or with splice-switching oligonucleotides targeting exon 5 of A3B. Our results underscore the clinical role of A3B and implicate alternative splicing of A3B as a mechanism that could be targeted to restrict APOBEC-mediated mutagenesis.


Subject(s)
Alternative Splicing , Biomarkers, Tumor/genetics , Cytidine Deaminase/genetics , Minor Histocompatibility Antigens/genetics , Mutagenesis , Proteins/genetics , Urinary Bladder Neoplasms/genetics , Biomarkers, Tumor/metabolism , Cytidine Deaminase/metabolism , Epoxy Compounds/pharmacology , Exons , Gene Expression Regulation, Neoplastic , HEK293 Cells , HeLa Cells , Hep G2 Cells , Humans , Isoenzymes , Macrolides/pharmacology , Minor Histocompatibility Antigens/metabolism , Phosphoproteins/antagonists & inhibitors , Phosphoproteins/metabolism , Progression-Free Survival , Proteins/metabolism , RNA Splicing Factors/antagonists & inhibitors , RNA Splicing Factors/metabolism , Urinary Bladder Neoplasms/enzymology , Urinary Bladder Neoplasms/mortality , Urinary Bladder Neoplasms/therapy
2.
Carcinogenesis ; 41(8): 1030-1037, 2020 08 12.
Article in English | MEDLINE | ID: mdl-31930332

ABSTRACT

Increased exposure to estrogen is associated with an elevated risk of breast cancer. Considering estrogen as a possible mutagen, we hypothesized that exposure to estrogen alone or in combination with the DNA-damaging chemotherapy drug, cisplatin, could induce expression of genes encoding enzymes involved in APOBEC-mediated mutagenesis. To test this hypothesis, we measured the expression of APOBEC3A (A3A) and APOBEC3B (A3B) genes in two breast cancer cell lines treated with estradiol, cisplatin or their combination. These cell lines, T-47D (ER+) and MDA-MB-231 (ER-), differed by the status of the estrogen receptor (ER). Expression of A3A was not detectable in any conditions tested, while A3B expression was induced by treatment with cisplatin and estradiol in ER+ cells but was not affected by estradiol in ER- cells. In The Cancer Genome Atlas, expression of A3B was significantly associated with genotypes of a regulatory germline variant rs17000526 upstream of the APOBEC3 cluster in 116 ER- breast tumors (P = 0.006) but not in 387 ER+ tumors (P = 0.48). In conclusion, we show that in breast cancer cell lines, A3B expression was induced by estradiol in ER+ cells and by cisplatin regardless of ER status. In ER+ breast tumors, the effect of estrogen may be masking the association of rs17000526 with A3B expression, which was apparent in ER- tumors. Our results provide new insights into the differential etiology of ER+ and ER- breast cancer and the possible role of A3B in this process through a mitogenic rather than the mutagenic activity of estrogen.


Subject(s)
Breast Neoplasms/genetics , Cytidine Deaminase/genetics , Estrogens/metabolism , Gene Expression Regulation, Neoplastic , Minor Histocompatibility Antigens/genetics , Mutagenesis , Receptors, Estrogen/metabolism , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Cisplatin/pharmacology , Estradiol/pharmacology , Glucose-6-Phosphate Isomerase , Humans , Proteins/genetics , Receptors, Estrogen/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...